| Vol. 5.13 – 16 April, 2021 |
| | | As GLP-1 receptor (GLP-1R) is unlikely expressed in hepatocytes, scientists aimed to compare such stimulation in mice and in mouse-hepatocytes; determined the involvement of GLP-1R, and clarified whether fibroblast growth factor 21 (FGF21) mediated certain functions of the GLP-1R agonist liraglutide. [Hepatology] |
|
|
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers describe a protocol to differentiate human induced pluripotent stem cells into hepatic stellate cells. [Nature Protocols] |
|
|
|
| Investigators demonstrated that chondroitin sulfate coated multilayered 50-nm nanoparticles encapsulating collagenase and silibinin broke down the dense collagen stroma, while silibinin inhibited activated hepatic stellate cells. [Carbohydrate Polymers] |
|
|
|
| Researchers showed that glycolysis was significantly enhanced, while the expression of brain and muscle arnt-like protein-1 (Bmal1) was downregulated in fibrotic liver tissues of mice, primary hepatic stellate cells (HSCs), and transforming growth factor-β1 (TGF-β1)-induced LX2 cells. [Acta Pharmaceutica Sinica B] |
|
|
|
| Scientists aimed to elucidate the role of Bone morphologic protein 9 (BMP9) signaling in hepatocellular carcinoma-cancer stem cells (HCC‐CSC) properties and to assess the therapeutic effect of BMP receptor inhibitors in HCC. [Molecular Oncology] |
|
|
|
| Investigators confirmed that p62 was up-regulated in hepatocellular carcinoma and its higher expression was associated with shorter overall survival in patients. [Cell Death & Disease] |
|
|
|
| Scientists developed a conditioned culture system composed of a small-molecule combination that could maintain hepatocyte morphology and functions over the long term. [Archives of Toxicology] |
|
|
|
| Researchers investigated the role of Krüppel-like factors (KLF7) in proliferation and migration of hepatocellular carcinoma (HCC) cells. [Cell and Bioscience] |
|
|
|
| The ischemia-reperfusion (I/R) liver injury rat model and the primary hepatocyte hypoxia/reoxygenation injury model were established. The biochemical indexes, inflammatory factor indexes, Th17/Treg balance and energy metabolism were evaluated. [Journal of Pharmacological Sciences] |
|
|
|
|
| The authors provide up-to-date information on the best use of currently available immunotherapies in hepatocellular carcinoma and the therapeutic strategies under development. [Nature Reviews Gastroenterology & Hepatology] |
|
|
|
| Scientists review the dynamic roles of inflammatory mediators in responses to sterile injury in the context of homeostasis and disease, the clinical implications of dysregulated hepatic immune activity and therapeutic developments to regulate liver-specific immunity. [Cellular & Molecular Immunology] |
|
|
|
| The authors provide the latest findings on critical signaling pathways governing hepatocellular carcinoma (HCC) behavior and using small molecules in the control of HCC both in vitro and in vivo models. [Cancer Cell International] |
|
|
|
|
| VBI Vaccines, Inc. announced data and next steps from the high-dose cohort of its Phase Ib/IIa clinical study of VBI-2601, the company’s hepatitis B immunotherapeutic candidate, in chronically-infected hepatitis B patients. [VBI Vaccines, Inc. (businesswire)] |
|
|
|
| Axcella, announced that it had achieved a key milestone with U.S. FDA clearance of an Investigational New Drug (IND) application for AXA1125, enabling the company to proceed directly into a Phase IIb clinical trial. [Axcella (businesswire)] |
|
|
|
|
|
|
|
| Translate Bio – Lexington, Massachusetts, United States |
|
|
|
| Institute of Hepatology – London, United Kingdom |
|
|
|
| Karolinska Institutet – Huddinge, Sweden |
|
|
|
| Spark Therapeutics – Philadelphia, Pennsylvania, United States |
|
|
|
| Cancer Research Center of Lyon – Lyon, France |
|
|
|
|